Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary

Frontiers in Oncology

Oncology

Mayumi Homma¹  Toshiko Yamochi¹  Yuya Hirasawa²  Toshiaki Tsurui²  Nana Iriguchi²  Risako Suzuki²  Ryotaro Ohkuma²  Hirotsugu Ariizumi²  Takuya Tsunoda²  Yutaro Kubota²  Atsushi Horiike²  Tomoyuki Ishiguro²  Kazuyuki Hamada³  Satoshi Wada⁴  Kiyoshi Yoshimura⁵ 

[1] Department of Pathology, Showa University School of Medicine, Tokyo, Japan;Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan;Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;Department of Clinical Diagnostic Oncology, Clinical Research Institute of Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan;Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan;

关键词: cancer of unknown primary;    p16;    5-fluorouracil;    cisplatin;    PD-1 antibody;    pembrolizumab;    squamous cell carcinoma;   

DOI  :  10.3389/fonc.2023.1231986

 received in 2023-05-31, accepted in 2023-06-22,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundCancer of unknown primary (CUP) is a malignant tumor without a known primary lesion with a frequency of 3−5%. It can be divided into favorable and unfavorable prognosis subsets. While recommended treatments are available for the former group, there is no established treatment for the latter. Here, we report the effective treatment of a 32-year-old woman with p16-positive squamous cell CUP with pembrolizumab plus 5-fluorouracil and cisplatin therapy.Case presentationA 32-year-old woman presented with metastatic lesions in the liver, lung, bone, cervical region, abdominal region, and pelvic lymph nodes. She was diagnosed with p16-positive squamous cell carcinoma of unknown primary origin. The patient received pembrolizumab plus 5-fluorouracil and cisplatin therapy, which markedly reduced the metastasis and improved her Eastern Cooperative Oncology Group performance status after two courses.ConclusionThis case report highlights the potential of pembrolizumab plus 5-fluorouracil and cisplatin therapy for treating CUP with an unfavorable prognosis. p16 positivity is worth examining for squamous cell carcinoma of unknown primary origin, and if present, this therapy should be considered a promising treatment option.

【 授权许可】

Unknown   
Copyright © 2023 Suzuki, Hamada, Ohkuma, Homma, Tsurui, Iriguchi, Ishiguro, Hirasawa, Ariizumi, Kubota, Horiike, Yoshimura, Wada, Yamochi and Tsunoda